Potential biomarker to predict risk of recurrence after nephrectomy for locally advanced kidney cancer

Currently, the search for a reliable biomarker to identify those patients who are at risk of the cancer coming back after nephrectomy for renal cell carcinoma (RCC) has not been successful. A recent study looked at a protein called kidney injury molecule-1 (KIM-1) in patients with RCC and whether this protein could be used to […]

read more

Neutrophil-lymphocyte ratio as a prognostic biomarker in high-risk locally advanced kidney cancer

An analysis of the data collected during the S-TRAC study, in which patients with high-risk, localised renal cell carcinoma (RCC) were treated with adjuvant sunitinib (after surgery), showed that sunitinib improved disease-free survival over placebo, but not overall survival. Researchers decided to look at biomarkers for disease-free survival in this study. In this study, a […]

read more

ESMO 2019: Results from SORCE clinical trial with adjuvant sorafenib

Results from the SORCE clinical trial to assess sorfenib as an adjuvant treatment for renal cell carcinoma (RCC) at intermediate or high risk of relapse were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. As for previous large randomised phase 3 clinical trials (ASSURE, PROTECT, and ATLAS) to […]

read more

CAR can be used to indicate survival in kidney cancer patients

A recent study with Japanese patients, published in Urologic Oncology last month, provides evidence to suggest that the ratio of two proteins in the blood (C-reactive protein and albumin ratio, CAR) before surgery is an independent prognostic indicator of overall survival, cancer-specific survival and recurrence-free survival for patients with renal cell carcinoma (RCC). Because CAR […]

read more

Adjuvant therapy for renal cell carcinoma

The following articles from various urology conferences in 2018 summarise the status of research with respect to adjuvant therapy after nephrectomy for people with localised renal cell carcinoma (RCC). Many adjuvant therapies have been assessed in clinical trials, such as radiotherapy, vaccines, immunotherapy, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKI), and checkpoint inhibitors. […]

read more

Adjuvant sunitinib may increase symptoms and reduce quality of life in kidney cancer

A recent article in Annals of Oncology┬áreports new patient-reported outcomes data from the S-TRAC study to suggest that adjuvant sunitinib treatment in patients with a high risk of recurrence of renal cell carcinoma (RCC) was linked to increased symptoms and a worse health-related quality of life (HRQoL) compared with placebo. The S-TRAC study showed that […]

read more
Showing all 6 results